SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Chris08 who wrote (2885)2/17/2012 12:35:44 PM
From: DewDiligence_on_SI  Read Replies (1) of 3661
 
HCV and HIV are fundamentally different; the latter integrates into the host genome, while the former does not, which allows HCV drug regimens to provide an outright cure for some patients.

So, the short answer to your question is that today's news cannot under any interpretation be considered a positive for GILD.

On the other hand, today’s news is a positive for biotech companies such as ACHN who are working on HCV drug classes other than nukes ( siliconinvestor.com ). Regards, Dew

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News